Cargando…

Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline

BACKGROUND: Hyperprolactinemia has been associated with changes in body composition and metabolic abnormalities. Normalization of prolactin (PRL) with dopamine agonists has been found to reverse these abnormalities. This study was designed to assess the anthropometric and metabolic alterations assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Pala, Nazir A., Laway, Bashir A., Misgar, Raiz A., Dar, Rayees A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650139/
https://www.ncbi.nlm.nih.gov/pubmed/26583049
http://dx.doi.org/10.1186/s13098-015-0094-4
_version_ 1782401453153845248
author Pala, Nazir A.
Laway, Bashir A.
Misgar, Raiz A.
Dar, Rayees A.
author_facet Pala, Nazir A.
Laway, Bashir A.
Misgar, Raiz A.
Dar, Rayees A.
author_sort Pala, Nazir A.
collection PubMed
description BACKGROUND: Hyperprolactinemia has been associated with changes in body composition and metabolic abnormalities. Normalization of prolactin (PRL) with dopamine agonists has been found to reverse these abnormalities. This study was designed to assess the anthropometric and metabolic alterations associated with prolactinoma and response of these abnormalities to cabergoline treatment. METHODS: In a non-randomised matched prospective design, 19 consecutive patients with prolactinoma (median PRL 118.6 (105.3) μg/L) and 20 controls were studied. The controls were age, gender and body mass index (BMI) matched. Anthropometric data and metabolic variables were studied at baseline, 3 and 6 months after cabergoline treatment. RESULTS: Patients with prolactinoma had increased level of fasting plasma glucose (P < .001), LDL-cholesterol (P = .001) and triglycerides (TG) (P = .009) as compared to age, gender and BMI matched healthy controls. There was a significant decrease of body weight at 3 months (P = .029), with a further decline at 6 months (P < .001) of cabergoline therapy. In addition, there was a significant decrement of BMI (P < .001), waist circumference (P = .003), waist-hip ratio (P = .03) and total body fat (P = .003) at 6 months of cabergoline treatment. A significant decline in plasma glucose (P < .001), total cholesterol (P = .009), LDL-cholesterol (P < .001) and TG (P < .001) was seen after 6 months of cabergoline treatment. CONCLUSIONS: Patients with prolactinoma have adverse metabolic profile compared with matched controls. Normalization of PRL with cabergoline corrects all the metabolic abnormalities.
format Online
Article
Text
id pubmed-4650139
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46501392015-11-19 Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline Pala, Nazir A. Laway, Bashir A. Misgar, Raiz A. Dar, Rayees A. Diabetol Metab Syndr Research BACKGROUND: Hyperprolactinemia has been associated with changes in body composition and metabolic abnormalities. Normalization of prolactin (PRL) with dopamine agonists has been found to reverse these abnormalities. This study was designed to assess the anthropometric and metabolic alterations associated with prolactinoma and response of these abnormalities to cabergoline treatment. METHODS: In a non-randomised matched prospective design, 19 consecutive patients with prolactinoma (median PRL 118.6 (105.3) μg/L) and 20 controls were studied. The controls were age, gender and body mass index (BMI) matched. Anthropometric data and metabolic variables were studied at baseline, 3 and 6 months after cabergoline treatment. RESULTS: Patients with prolactinoma had increased level of fasting plasma glucose (P < .001), LDL-cholesterol (P = .001) and triglycerides (TG) (P = .009) as compared to age, gender and BMI matched healthy controls. There was a significant decrease of body weight at 3 months (P = .029), with a further decline at 6 months (P < .001) of cabergoline therapy. In addition, there was a significant decrement of BMI (P < .001), waist circumference (P = .003), waist-hip ratio (P = .03) and total body fat (P = .003) at 6 months of cabergoline treatment. A significant decline in plasma glucose (P < .001), total cholesterol (P = .009), LDL-cholesterol (P < .001) and TG (P < .001) was seen after 6 months of cabergoline treatment. CONCLUSIONS: Patients with prolactinoma have adverse metabolic profile compared with matched controls. Normalization of PRL with cabergoline corrects all the metabolic abnormalities. BioMed Central 2015-11-14 /pmc/articles/PMC4650139/ /pubmed/26583049 http://dx.doi.org/10.1186/s13098-015-0094-4 Text en © Pala et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Pala, Nazir A.
Laway, Bashir A.
Misgar, Raiz A.
Dar, Rayees A.
Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline
title Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline
title_full Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline
title_fullStr Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline
title_full_unstemmed Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline
title_short Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline
title_sort metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650139/
https://www.ncbi.nlm.nih.gov/pubmed/26583049
http://dx.doi.org/10.1186/s13098-015-0094-4
work_keys_str_mv AT palanazira metabolicabnormalitiesinpatientswithprolactinomaresponsetotreatmentwithcabergoline
AT lawaybashira metabolicabnormalitiesinpatientswithprolactinomaresponsetotreatmentwithcabergoline
AT misgarraiza metabolicabnormalitiesinpatientswithprolactinomaresponsetotreatmentwithcabergoline
AT darrayeesa metabolicabnormalitiesinpatientswithprolactinomaresponsetotreatmentwithcabergoline